Pfizer Inc.'s new experimental heart drug is dead, but the dual approach the company was testing — boosting good cholesterol while lowering the bad — is very much alive, specialists said Monday. A drug already on the market, Niaspan, raises good cholesterol without serious risks, and a large federal study is testing it with statin medications — the very thing Pfizer was trying to do before being forced to abandon its drug, torcetrapib, because of safety problems.>>> Discuss This Story
